GetTopicDetailResponse(id=60de101462b2, topicName=馬昔騰坦, introduction=馬昔騰坦, content=null, image=null, comments=4, allHits=1828, url=https://h5.medsci.cn/topic?id=101462, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=79510, tagList=[TagDto(tagId=79510, tagName=馬昔騰坦)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2118573, encodeId=94f921185e3ff, content=<a href='/topic/show?id=a7b116558d6' target=_blank style='color:#2F92EE;'>#Sotatercept#</a>治療<a href='/topic/show?id=0bad820e112' target=_blank style='color:#2F92EE;'>#肺動(dòng)脈高壓#</a>3期臨床試驗(yàn)達(dá)終點(diǎn)。從1995年以來已經(jīng)陸續(xù)有10多款藥物獲批，機(jī)制上基本分成了幾大類：前列環(huán)素及類似物（PGI2），包括<a href='/topic/show?id=c5fb10551674' target=_blank style='color:#2F92EE;'>#依前列醇#</a>Epoprostenol、<a href='/topic/show?id=b4c460222ae' target=_blank style='color:#2F92EE;'>#曲前列環(huán)素#</a>Treprostinil、<a href='/topic/show?id=e715256693b' target=_blank style='color:#2F92EE;'>#伊洛前列素#</a>Iloprost、<a href='/topic/show?id=f1a610551eb1' target=_blank style='color:#2F92EE;'>#司來帕格#</a><a href='/topic/show?id=ce571611593' target=_blank style='color:#2F92EE;'>#Selexipag#</a>等；<a href='/topic/show?id=8a4610551847' target=_blank style='color:#2F92EE;'>#磷酸二酯酶5抑制劑#</a>（PDE5），包括<a href='/topic/show?id=0a1b904e96c' target=_blank style='color:#2F92EE;'>#西地那非#</a>和<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他達(dá)拉非#</a>等；<a href='/topic/show?id=aa073045525' target=_blank style='color:#2F92EE;'>#內(nèi)皮素受體拮抗劑#</a>（ETA/ETB），包括<a href='/topic/show?id=60b864948f2' target=_blank style='color:#2F92EE;'>#波生坦#</a>、<a href='/topic/show?id=bf96458280c' target=_blank style='color:#2F92EE;'>#安立生坦#</a>、<a href='/topic/show?id=60de101462b2' target=_blank style='color:#2F92EE;'>#馬昔騰坦#</a><a href='/topic/show?id=57fe1121e58' target=_blank style='color:#2F92EE;'>#Macitentan#</a>等；<a href='/topic/show?id=3add105519f0' target=_blank style='color:#2F92EE;'>#可溶性鳥苷酸環(huán)化酶激動(dòng)劑#</a>（sGC），包括<a href='/topic/show?id=ae6b3228332' target=_blank style='color:#2F92EE;'>#利奧西呱#</a><a href='/topic/show?id=872515489a0' target=_blank style='color:#2F92EE;'>#Riociguat#</a>。Sotatercept在選擇基線病情較輕患者的情況下，有效性數(shù)據(jù)與此前已獲批的單藥或聯(lián)用方案對(duì)比并不占?jí)旱剐詢?yōu)勢(shì)。<a href='/topic/show?id=60c232154fc' target=_blank style='color:#2F92EE;'>#創(chuàng)新藥物#</a>, objectTitle=NEJM：Sotatercept治療肺動(dòng)脈高壓3期臨床試驗(yàn)達(dá)終點(diǎn)（STELLAR研究）, objectType=article, longId=762303, objectId=b491e6230331, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230309/1678386039378_4754896.png, objectUrl=/article/show_article.do?id=b491e6230331, replyNumber=0, likeNumber=209, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b491e6230331, moduleTitle=NEJM：Sotatercept治療肺動(dòng)脈高壓3期臨床試驗(yàn)達(dá)終點(diǎn)（STELLAR研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b491e6230331)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1971792, encodeId=6b2919e1792e4, content=<a href='/topic/show?id=60de101462b2' target=_blank style='color:#2F92EE;'>#馬昔騰坦#</a>, objectTitle=南京正大天晴「馬昔騰坦片」首仿即將獲批, objectType=article, longId=201025, objectId=d8e62010253f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8e62010253f, replyNumber=0, likeNumber=113, createdTime=2020-11-04, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8e62010253f, moduleTitle=南京正大天晴「馬昔騰坦片」首仿即將獲批, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d8e62010253f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971791, encodeId=631e19e1791d0, content=<a href='/topic/show?id=60de101462b2' target=_blank style='color:#2F92EE;'>#馬昔騰坦#</a>, objectTitle=喜大普奔|門靜脈高壓相關(guān)性肺動(dòng)脈高壓（PoPH）顯示傲樸舒?（馬昔騰坦）顯著改善肺血管阻力, objectType=article, longId=150082, objectId=7e5f150082d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e5f150082d9, replyNumber=0, likeNumber=121, createdTime=2019-06-03, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e5f150082d9, moduleTitle=喜大普奔|門靜脈高壓相關(guān)性肺動(dòng)脈高壓（PoPH）顯示傲樸舒?（馬昔騰坦）顯著改善肺血管阻力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7e5f150082d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971790, encodeId=f29d19e179014, content=<a href='/topic/show?id=60de101462b2' target=_blank style='color:#2F92EE;'>#馬昔騰坦#</a>, objectTitle=Circulation：馬昔騰坦治療艾森曼格綜合征的評(píng)估, objectType=article, longId=147398, objectId=e49914e3981f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e49914e3981f, replyNumber=0, likeNumber=134, createdTime=2019-06-02, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e49914e3981f, moduleTitle=Circulation：馬昔騰坦治療艾森曼格綜合征的評(píng)估, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e49914e3981f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
